Lipocine Regains Complinace With Nasdaq Minimum Bid Price Requirement
SALT LAKE CITY, July 13, 2020 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) on July 9, 2020 indicating that…
Comments Off on Lipocine Regains Complinace With Nasdaq Minimum Bid Price Requirement